Aldeyra Therapeutics was founded in 2004 and is headquartered in Lexington, US

Aldeyra Therapeutics has an office in Lexington

Lexington, US (HQ)

131 Hartwell Ave

USD

## Net income (Q1, 2017) | (5.1 m) |

## EBIT (Q1, 2017) | (5.1 m) |

## Market capitalization (21-Jul-2017) | 65.5 m |

## Cash (31-Mar-2017) | 19.3 m |

Aldeyra Therapeutics's current market capitalization is $65.5 m.

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## R&D expense | 3.7 m | 7.6 m | 13.2 m |

## General and administrative expense | 3.6 m | 4.4 m | 5.5 m |

## Operating expense total | (7.3 m) | (12 m) | (18.7 m) |

## EBIT | (18.7 m) | ||

## Interest expense | (244.2 k) | (112.3 k) | (105.5 k) |

## Interest income | 3 | 11.1 k | 102 k |

## Net Income | (9.6 m) | (12.1 m) | (18.7 m) |

USD | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|

## R&D expense | 3.5 m | 2.8 m | 3.4 m | 3.4 m | ||

## General and administrative expense | 1.5 m | 1.5 m | 1.4 m | 1.7 m | ||

## Operating expense total | 5 m | 4.3 m | 4.8 m | 5.1 m | ||

## EBIT | (5 m) | (4.3 m) | (4.8 m) | (5.1 m) | ||

## Interest expense | (25 k) | (27.8 k) | (26.7 k) | (26.8 k) | ||

## Interest income | 24.7 k | 22 k | 27.8 k | 31.6 k | ||

## Net Income | (4.4 m) | (7.7 m) | (5 m) | (9.3 m) | (14 m) | (5.1 m) |

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 8.5 m | 14.6 m | 12 m |

## Inventories | 232.6 k | 497.6 k | 218.7 k |

## Current Assets | 8.8 m | 28.1 m | 25.1 m |

## Total Assets | 8.8 m | 28.2 m | 25.2 m |

## Accounts Payable | 341.3 k | 851.2 k | 275.4 k |

## Current Liabilities | 1.3 m | 2.1 m | 2.3 m |

## Total Liabilities | 3.5 m | ||

## Additional Paid-in Capital | 1.1 m | 83.5 m | 98.9 m |

## Retained Earnings | (46.5 m) | (58.6 m) | (77.3 m) |

## Total Equity | 6.3 m | 24.9 m | 21.6 m |

## Financial Leverage | 1.4 x | 1.1 x | 1.2 x |

USD | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|

## Cash | 33.6 m | 30.6 m | 10.1 m | 17.6 m | 14.6 m | 19.3 m |

## Current Assets | 33.8 m | 31.2 m | 23.3 m | 32.8 m | 29.1 m | 31.5 m |

## Total Assets | 33.9 m | 31.4 m | 23.4 m | 32.9 m | 29.2 m | 31.5 m |

## Accounts Payable | 629.3 k | 743.6 k | 578 k | 823.3 k | 733.6 k | 694.9 k |

## Current Liabilities | 1.4 m | 1.4 m | 1.8 m | 2.4 m | 2.6 m | 2.4 m |

## Additional Paid-in Capital | 82.4 m | 82.9 m | 84.1 m | 97.4 m | 98.3 m | 110.4 m |

## Retained Earnings | (50.9 m) | (54.2 m) | (63.6 m) | (67.9 m) | (72.6 m) | (82.4 m) |

## Total Equity | 31.5 m | 28.7 m | 20.5 m | 29.5 m | 25.7 m | 28 m |

## Financial Leverage | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (5.2 m) | (12.1 m) | (18.7 m) |

## Depreciation and Amortization | 1.1 k | 18.8 k | 35.8 k |

## Inventories | (224.2 k) | (265 k) | 278.9 k |

## Accounts Payable | (559) | 509.9 k | (575.7 k) |

## Cash From Operating Activities | 5.3 m | 6.1 m | (15.1 m) |

## Cash From Investing Activities | (14.1 k) | (13 m) | (225.2 k) |

## Cash From Financing Activities | 10.1 m | 28.5 m | 12.7 m |

## Interest Paid | 96.8 k | 74.3 k | 78.1 k |

USD | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|

## Net Income | (4.4 m) | (7.7 m) | (5 m) | (9.3 m) | (14 m) | (5.1 m) |

## Depreciation and Amortization | 4 k | 10.6 k | 8.1 k | 17.1 k | 26.5 k | 9.7 k |

## Accounts Payable | 288.1 k | 402.3 k | (273.1 k) | (27.9 k) | (117.6 k) | 419.5 k |

## Cash From Operating Activities | (3.4 m) | (6.3 m) | (4.5 m) | (7.7 m) | (11.2 m) | (4.2 m) |

## Cash From Investing Activities | (31.9 k) | (86.1 k) | (9.2 k) | (2.1 m) | (1.5 m) | 891.5 k |

## Cash From Financing Activities | 28.5 m | 28.5 m | (9.8 k) | 12.8 m | 12.7 m | 10.6 m |

## Interest Paid | 37.7 k | 55.8 k | 19.5 k | 39.1 k | 58.7 k |

Y, 2017 | |
---|---|

## Financial Leverage | 1.1 x |